Inventor · disambiguated record
Ingo Klagge
Also filed as: KLAGGE INGO · KLAGGE INGO MARKUS
5 granted patents·6 pending applications·13 citations·filing 2007–2020
74Inventor score
Top patents by PatentIndex Score
11 records- 0178US8574573B2Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disordersCARBALLIDO HERRERA JOSE M·Filed 2011·Granted Nov 5, 2013·5 cites·9 claims
- 0276US8299221B2LINGO binding molecules and pharmaceutical use thereofWALMSLEY ADRIAN·Filed 2007·Granted Oct 30, 2012·7 cites·6 claims
- 0369US9428583B2Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodiesCONG FENG·Filed 2011·Granted Aug 30, 2016·1 cites·52 claims
- 0459US2020377603A1Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodiesNOVARTIS AG·Filed 2020·Application pending·0 cites
- 0557US8999708B2Anti-IL12Rβ1 antibodies and their use in treating autoimmune and inflammatory disordersCARBALLIDO HERRERA JOSE M·Filed 2013·Granted Apr 7, 2015·0 cites·16 claims
- 0656US8945548B2Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disordersCARBALLIDO HERRERA JOSE M·Filed 2013·Granted Feb 3, 2015·0 cites·11 claims
- 0752US2014255415A1LINGO Binding Molecules and Pharmaceutical Use ThereofCORTES-CROS MARTA·Filed 2014·Application pending·0 cites
- 0851US2014037639A1LINGO Binding Molecules and Pharmaceutical Use ThereofCORTES-CROS MARTA·Filed 2013·Application pending·0 cites
- 0950US2017362326A1Compositions and Methods of Use for Therapeutic Low Density Lipoprotein-related protein 6 (LRP6) AntibodiesNOVARTIS AG·Filed 2016·Application pending·0 cites
- 1047US2013071400A1LINGO binding molecules and Pharmaceutical Use ThereofWALMSLEY ADRIAN·Filed 2012·Application pending·0 cites
- 1134US2010291106A1Compositions and methods for antibodies targeting complement protein c3bNOVARTIS AG·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →